AI & Analytics Consumption: Insights on Demand

Posted by Arun Shastri on Wed, Oct 02, 2019

This blog post is the fifth in a series on the impact that AI will have on different business aspects of pharma.

The past few years have seen an explosion of data, and with it, the need to make use of it. Gathering and stitching together internal and external data sources presents one set of challenges, but what about the analysts who struggle to leverage all of this data? How can they keep up with increasing demands for data-driven insights from the entire organization? How can we empower the whole organization to have access to these critical insights? Here’s a hint: AI is part of the solution.


>
Read More

AI & Clinical Trials: Poised for Disruption

Posted by Arun Shastri on Wed, Sep 11, 2019

This blog post is the third in a series on the impact that AI will have on different business aspects of pharma.

We always tell our clients to start small with AI. As Pratap Khedkar shared in my first interview, it’s important to start with clear, specific use cases. For some aspects of the business, it may take some time to carefully consider what these specific use cases are and what opportunities AI can create. Clinical trials present no such difficulties. The opportunities to improve efficiencies are numerous and clear, and AI has begun to make an impact. The industry is aware of the inefficiencies that abound in clinical trial design and execution and is eager to solve them.


>
Read More

AI & Pharma: Start Small But Think Big

Posted by Arun Shastri on Wed, Jul 24, 2019

This blog post is the first in a series on the impact that AI will have on different business aspects of pharma.

AI has been here for many decades, but the buzz around this latest wave of AI is louder than any I can remember. You can find articles about AI in every publication and medium. These articles deal mostly with broad themes, rarely delving into how AI might be applied in our work lives. There are plenty of stories about self-driving cars and the latest human expert to be outwitted by an algorithm. But what about the unsexy business that most of us find ourselves in? How can we apply AI to improve customer interactions, maximize product launches, optimize clinical trial operations, or find patient insights?


>
Read More

The Evolving Data Landscape Will Transform Healthcare. Here Are Four Trends to Watch.

Posted by Paul Darling on Fri, Jun 28, 2019

Oladele Ojo co-wrote this blog post with Paul Darling. 

The healthcare system generates approximately a zettabyte (a trillion gigabytes) of data each year, which includes both classic data from sources such as EHRs, diagnostics and genetics, as well as newer data sources such as gut biome sensors, wearable devices and environmental monitors, and social media. Consequently, it’s now possible to quantify a person across three dimensions of human existence: biological, environmental and digital/social.


>
Read More

First Launch Commercialization Strategy: Go It Alone or Partner?

Posted by Renuka Agarwal on Fri, Feb 01, 2019

Ben Hohn, Cody Powers and Judith Kulich co-wrote this article with Renuka Agarwal.

The 2019 JPMorgan Chase Healthcare Conference kicked off with a bang as Eli Lilly announced its acquisition of Loxo Oncology for $8 billion. Loxo, a young biotechnology company that partnered with Bayer to launch its first asset, Vitrakvi, in 2018, isn’t a unique story: In today’s environment, the number of first launches for U.S.-based companies—defined by ZS as the first marketed assets of companies that have FDA “novel” status—is rapidly increasing. There were only three first launches from U.S.-based companies in 2011 compared to an astounding 16 first launches in 2018, primarily in oncology, according to ZS research.


>
Read More